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Abstract
Background
HPTN071(PopART) is a 3-arm community-randomised study in 21 peri-urban/urban com-
munities in Zambia and the Western Cape of South Africa, with high HIV prevalence and
high mobility especially among young adults. In Arm A communities, from November 2013
community HIV care providers (CHiPs) have delivered the “PopART” universal-test-and-
treat (UTT) package in annual rounds, during which they visit all households and offer HIV
testing. CHiPs refer HIV-positive (HIV+) individuals to routine HIV clinic services, where uni-
versal ART (irrespective of CD4 count) is offered, with re-visits to support linkage to care.
The overall goal is to reduce population-level adult HIV incidence, through achieving high
HIV testing and treatment coverage.
Methods and findings
The second annual round was June 2015-October 2016. Included in analysis are all individ-
uals aged15 years who consented to participate, with extrapolation to the total population.
Our three main outcomes are (1) knowledge of HIV+ status (2) ART coverage, by the end of
Round 2 (R2) and compared with the start of R2, and (3) retention on ART on the day of con-
senting to participate in R2. We used “time-to-event” methods to estimate the median time
to start ART after referral to care. CHiPs visited 45,631 households during R2, ~98% of the
estimated total across the four communities, and for 94% (43,022/45,631) consent was
given for all household members to be listed on the CHiPs’ electronic register; 120,272 indi-
viduals aged15 years were listed, among whom 64% of men (37,265/57,901) and 86%
(53,516/62,371) of women consented to participate in R2. We estimated there were 6,521
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HIV+ men and 10,690 HIV+ women in the total population of visited households; and that
~80% and ~90% of HIV+ men and women respectively knew their HIV+ status by the end of
R2, fairly similar across age groups but lower among those who did not participate in Round
1 (R1). Among those who knew their HIV+ status, ~80% of both men and women were on
ART by the end of R2, close to 90% among men aged45 and women aged35 years, but
lower among younger adults, those who were resident in R1 but did not participate in R1,
and those who were newly resident in the area of the community in which they were living in
R2. Overall ART coverage was ~65% among HIV+ men and ~75% among HIV+ women,
compared with the cumulative 90–90 target of 81%. Among those who reported ever taking
ART, 93% of men and 95% of women self-reported they were on ART and missed 0 pills in
the last 3 days. The median time to start ART after referral to care was ~6 months in R2, sim-
ilar across the age range 25–54 years, compared with ~9.5 months in R1. The two main limi-
tations to our findings were that a comparison with control-arm communities cannot be
made until the end of the study; and that to extrapolate to the total population, assumptions
were required about individuals who were resident, but did not participate, in R2.
Conclusions
Overall coverage against the 90–90 targets was high after two years of intervention, but was
lower among men, individuals aged 18–34 years, and those who did not participate in R1.
Our findings reflect the relative difficulties for CHiPs to contact men at home, compared with
women, and that it is challenging to reach high levels of testing and treatment coverage in
communities with substantial mobility and in-migration. The shortened time to start ART
after referral to care in R2, compared with R1, was likely attributable to multiple factors
including an increased focus of the CHiPs on linkage to care; increasing community accep-
tance and understanding of the CHiPs, and of ART and UTT, with time; increased coordina-
tion with the clinics to facilitate linkage; and clinic improvements.
Introduction
The UNAIDS 90-90-90 targets, set for 2020, are that 90% of HIV-positive individuals know
their HIV-positive status, 90% of those who know their HIV-positive status are on antiretrovi-
ral therapy (ART), and 90% of those taking ART are virally suppressed[1]. These targets corre-
spond to 81% of HIV-positive individuals being on ART and 73% of HIV-positive individuals
being virally suppressed, with the overall goal of improving the health of people living with
HIV and decreasing HIV transmission at the population level.
Evidence that universal ART, irrespective of CD4 count, would contribute to improving the
health and survival of people living with HIV became available from two randomized con-
trolled trials in 2015[2, 3]. Modelling, drawing on the findings of the HPTN052 trial, has
shown that reaching 90-90-90 has the potential to decrease transmission at population level[4–
6], although this remains to be proven in a rigorously designed trial. Empirical findings from
two population-intervention platforms have also indicated that higher ART coverage levels are
associated with lower HIV incidence in the general adult population, through a comparison
across time periods (Rakai district, Uganda) or across areas (rural KwaZulu Natal, South
Africa)[7, 8].
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In contrast, the community-randomised ANRS 12249 TasP trial of universal-testing-and-
treatment (UTT), conducted in rural KwaZulu Natal in South Africa, found no evidence of an
effect of the intervention on HIV incidence[9, 10]. However, the percentage of HIV-positive
adults who were on ART at the end of this trial was similar in the two study arms, and much
lower than the cumulative 90–90 target of 81%[10], so the trial findings do not refute the
hypothesis that UTT can reduce HIV transmission. Three other community-randomised trials
(CRTs) to evaluate the effect of UTT interventions on population-level adult HIV incidence
have been underway since 2013–14, and will complete in 2017–19[11–13]. They will provide
evidence from rural settings in Uganda and Kenya[13], rural and peri-urban settings in
Botswana[12], and peri-urban and urban settings in Zambia and the Western Cape of South
Africa[11].
During 2012–2014, most countries in sub-Saharan Africa were far from reaching the 90-90-
90 targets[14, 15]. Whilst WHO guidelines were updated in 2015 to recommend universal
ART[16], this might not be sufficient to reach the 90-90-90 targets; innovations to increase the
uptake of HIV testing, linkage to HIV care following an HIV-positive diagnosis, the rapidity of
ART initiation following linkage to care, and treatment adherence, may also be required. In
2016, “Population-based HIV Impact Assessment” (PHIA) surveys found that in Malawi
~70%, and in Zambia and Zimbabwe ~60%, of all HIV-positive adults (regardless of their self-
reported knowledge of their HIV-positive status and use of ART) were virally suppressed,
showing that the way in which these countries have scaled up testing, treatment, and treatment
monitoring and adherence support, services, has enabled them to approach the 90-90-90 tar-
gets[17]. Additionally, a survey conducted in 2013–2015 in Botswana, as part of the Botswana-
Combination-Prevention-Project (BCPP) CRT, found that ~70% of all HIV-positive adults
were virally suppressed prior to the roll-out of study interventions[12]. The findings from
these four settings indicate that, with appropriate interventions, it may be possible to reach the
cumulative 90-90-90 target.
The HPTN 071 (PopART) trial is a 3-arm CRT in 21 large peri-urban/urban communities
in Zambia and the Western Cape of South Africa, with high HIV prevalence and high mobility
especially among young adults, and a total study population of ~1 million people[11]. The
study is testing the impact on HIV incidence of a household-based combination HIV preven-
tion approach (Arms A and B) provided by community HIV care providers (CHiPs) compared
with standard-of-care (Arm C). In Arm A and B communities, CHiPs have offered universal
testing and support for linkage to HIV care and treatment adherence, while in Arm A (but not
Arm B) universal treatment has been delivered through routine government services, from Jan-
uary 2014. During May/June 2016 in Zambia, and during October 2016 in South Africa, the
clinics in all Arm B and Arm C communities transitioned to offer universal treatment.
Across the four Arm A Zambian communities, we have previously estimated that immedi-
ately prior to the first year of intervention ~44% of HIV-positive adults were on ART, and that
this increased to ~61% by the end of the first year of intervention in mid-2015[18]. An impor-
tant finding from year 1 was that ART coverage was lower among men than women, and
lower among younger than older adults, consistent with other studies[12, 17]. In this paper, we
report findings from these same four Zambia communities about how close we have come to
the 90–90 targets by October 2016, after two years of delivering the PopART UTT interven-
tion, disaggregated by gender and age group and including information on adolescents aged
15–17 years for the first time. We also disaggregate our findings according to whether or not
an individual participated in year 1, because it became apparent during year 2 that there was
high mobility within, and into and out of, the study communities. In addition, we present find-
ings about whether the time to start ART after referral to HIV care by CHiPs was shortened in
the second year of intervention compared with the first year.
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Methods
Setting
The study population consists of the four Arm A communities in Zambia, across which adult
HIV prevalence ranges from ~10% to ~25% and the total population is ~200,000[11].
PopART intervention
In Arm A, CHiPs deliver the PopART “UTT” intervention. This consists of offering universal
home-based HIV testing, referral of HIV-positive (HIV+) individuals to routine government HIV
clinic services that offer universal ART, and re-visits to HIV-positive individuals to support link-
age to HIV care and retention on ART. The PopART intervention also includes various other ser-
vices—HIV education, referral to medical male circumcision services, referral to antenatal care
for pregnant women, reproductive health and family planning referrals, tuberculosis symptom
screening followed by referral of those with symptoms to the clinic for diagnosis, sexually-trans-
mitted-infection symptom screening followed by referral of those with symptoms to the clinic for
diagnosis, and condom provision—providing a combination HIV prevention package[18].
Before the start of the PopART intervention, each of the intervention communities were divided
into “zones” with on average ~500 households. CHiPs work in pairs, with each team responsible for
one zone. CHiPs deliver the “PopART” intervention in annual “rounds”, during which they visit all
households (irrespective of whether or not a household was resident during a previous round), offer
to explain the intervention, and ask permission to enumerate (list) all household members. The first
“annual round” (Round 1) was from November 2013 to June 2015, and the second “annual round”
(Round 2) was from June 2015 to October 2016, with the intervention rolled out across communi-
ties over a 1–2 month period, and within communities across all zones simultaneously.
In Round 1 (R1) and Round 2 (R2), CHiPs aimed to contact all adults (18 years) at least once,
and from early in Round 2 (October 1 2015) this was also the aim for those aged 15–17 years. The
CHiPs work systematically through their zone, making appointments and repeat visits to try to
contact those who are initially absent from home, or who are initially unsure if they wish to partici-
pate and/or test for HIV. During R2, new strategies were implemented to try to increase the per-
centage of men who were contacted by the CHiPs, and to facilitate more rapid linkage to HIV care
among HIV-positive individuals. In some zones, CHiPs periodically supplemented their household
visits with “zonal campaigns” during which they offered services in a non-household setting, and
the frequency with which they worked early and late in the day and on weekends was increased.
With respect to linkage to care, there was a greater focus on this in R2 compared with R1, with tar-
getted follow-up of individuals who had been referred but not yet linked to care, increased coordi-
nation between the CHiPs and the clinic to facilitate linkage, and clinic improvements.
Data collection
CHiPs record information on electronic registers, as described elsewhere[18]. Clients verbally
consent to participation in the intervention, and provide written consent for HIV counselling
and testing. Data captured electronically includes consent to participate in the intervention,
self-reported HIV status, the date of the most recent HIV test, uptake of HIV testing, the out-
come of HIV testing by CHiPs, and which referrals were given.
Individuals are “known HIV-positive” to the CHiPs in R2 if they participated in R2 and
either (i) self-reported or tested HIV-positive in R1, and verbally confirmed their HIV-positive
status in R2 (ii) self-reported HIV-positive for the first time in R2, or (iii) tested HIV-positive
with CHiPs in R2. For those who confirmed or self-reported they were HIV-positive in R2,
self-reported data were collected at the time of the annual R2 visit on whether they were
Towards 90-90: Findings after 2 years of a UTT intervention in Zambia
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registered for HIV care, had ever taken ART, were currently on ART, and for those who
reported taking ART how many pills they had missed in the previous three days. For individu-
als who reported they were registered for HIV care, CHiPs asked to see the patient ART card;
if the card was provided, the ART card number was recorded.
For all who were known HIV-positive following the R2 annual visit, CHiPs were expected
to collect updated information at follow-up visits about whether an individual was still resident
in the zone, and (if the individual was contacted) self-reported information on registration for
HIV care, ART initiation, and ART adherence.
Outcomes and data analysis
Analyses were done for individuals aged15 years, and separately for men and women. The
indicators of intervention coverage used for our analyses were determined at the start of the
trial; when the UNAIDS 90-90-90 targets were announced at a later stage during 2014, we
extended our indicators to include estimates of coverage against these targets.
Among outcomes that were measured directly among individuals who consented to partici-
pate in R2, five are of central interest because they represent the key steps in the HIV testing-
and-treatment cascade:
1. the percentage who consented to participate in R2, among all household members who
were enumerated;
2. the percentage who knew their HIV status following the R2 annual visit, among all who
consented to participate in R2;
3. the percentage who were on ART by the end of R2, among known HIV-positive individuals
who remained resident in the same zone of the community at the end of R2;
4. the percentage who were retained on ART on the date of consenting to participate in R2,
among known HIV-positive individuals who ever reported to CHiPs (during R1 and/or at
the R2 annual visit) that they had ever taken ART;
5. the time to start ART after referral to HIV care by CHiPs in R2, among known HIV-posi-
tive individuals who were not on ART on the date of referral.
For knowledge of HIV status following the R2 annual visit, we applied a strict definition:
that someone knew their HIV status if they either self-reported HIV-positive, accepted the
offer of HIV testing with CHiPs and received their result, or self-reported they had tested
HIV-negative in the previous 3 months. We applied a less strict definition for knowledge of
HIV status immediately prior to the R2 visit: that someone knew their HIV status if they either
self-reported HIV-positive, self-reported they had tested HIV-negative in the previous 12
months, or tested HIV-negative with CHiPs in R1.
We used the Kaplan-Meier “time-to-event” method to estimate the time from first referral
in R2 to ART initiation, and Cox regression for analysis of whether the time to ART initiation
differed by gender or age group, with censoring on the date of the last follow-up visit at which
an individual was contacted in person for those who did not start ART, and using follow-up
data up to September 30 2017.
Estimation of the number of HIV-positive individuals in the population,
and the first and second “90s”
Methods for estimating the number of HIV-positive individuals, and the first and second
90s, have been described in detail elsewhere, and have previously been applied to the R1
Towards 90-90: Findings after 2 years of a UTT intervention in Zambia
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intervention data from Arm A communities in Zambia[18]. The methods are summarized
here.
First, we estimated the number of HIV-positive individuals among all who participated in
R2 (those who consented to participate, and also had health counselling information
recorded), as the sum of: (1) the number who were known by the CHiPs to be HIV-positive;
and (2) an estimated number among those whose HIV status was not known to CHiPs, assum-
ing that HIV prevalence in this group was the same as among those who accepted testing in
R2. We extrapolated to the total population who were enumerated in R2 by assuming that
HIV prevalence among non-participants in R2 was the same as among participants.
We calculated the first and second 90s, among individuals who participated in R2, as
follows:
1. the proportion of HIV-positive individuals who knew their HIV-positive status immediately
before Round 2 = the total who self-reported they were HIV-positive, divided by the esti-
mated number of HIV-positive individuals;
2. the proportion who knew their HIV-positive status by the end of Round 2 = the total who
were known by the CHiPs to be HIV-positive following the R2 annual visit, divided by the
estimated number of HIV-positive individuals;
3. the proportion who were on ART immediately after the Round 2 annual visit, among those
who knew their HIV-positive status = the total who self-reported they were on ART,
divided by the number who were known by the CHiPs to be HIV-positive immediately fol-
lowing the R2 annual visit;
4. the proportion who were on ART by the end of Round 2, among those who knew their HIV-
positive status = the total who self-reported they were on ART at the last CHiP visit made
during R2, divided by the number who were known by the CHiPs to be HIV-positive and
who remained resident in the same zone of the community according to the last informa-
tion collected during R2.
We extrapolated to the total population by assuming that (1) knowledge of HIV-positive
status and ART uptake among non-participants in R2 was the same as among participants
immediately before the R2 annual visit and (2) these outcomes did not change during R2,
equivalent to assuming that non-participants did not receive HIV testing or treatment services
during R2.
For R1, all estimation was done with stratification on gender, community of residence,
and age group. For R2, we additionally stratified by six categories of prior residency and
participation: (1) newly resident in the zone of the community (among whom information
was not collected about whether they had moved from within, or from outside, the com-
munity); (2) resident in the same zone of the community in R1, but did not participate in
R1; (3) participated in R1 and self-reported HIV-positive; (4) participated in R1 and was
newly diagnosed HIV-positive; (5) participated in R1 and tested HIV-negative; (6) partici-
pated in R1 but did not self-report HIV-positive and did not accept the offer of HIV test-
ing in R1. The stratum-specific estimates of all numbers (for example, the number of
HIV-positive individuals, the number of HIV-positive individuals who knew their HIV-
positive status) were then summed to provide summaries separately for each age group,
according to participation and residency (yes or no) in R1, and overall. We also used sen-
sitivity analysis for key assumptions, as for estimates of progress towards 90–90 after one
year of intervention[18].
Towards 90-90: Findings after 2 years of a UTT intervention in Zambia
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Comparison with Arm C (standard-of-care) communities, and findings
from Arm A communities in South Africa
We are bound by strict trial oversight procedures that preclude the publication of any compar-
ison across trial arms while the study is ongoing, and because there is no “PopART” interven-
tion in the communities in the control arm there are no CHiP intervention data collected in
Arm C.
As explained previously, we did not report estimates of coverage against the 90–90 targets
after one year of intervention in South Africa because some challenges were encountered there
with data collected as part of the CHiP intervention[18]. Several of these challenges were
resolved by the start of year 2, but some new challenges emerged. Following intensive efforts,
these challenges were fully resolved by early 2016 but not in time for it to be possible to reliably
estimate coverage against the 90–90 targets after two years of intervention.
Ethical considerations
The study and all the above procedures were approved by the ethics committees of the London
School of Hygiene & Tropical Medicine and the University of Zambia. The study is sponsored
by NIH.
Results
Cascade from enumeration, through participation, to knowledge of HIV
status, among all individuals
CHiPs visited 45,631 households during R2, ~98% of the total (as estimated from a census con-
ducted by the study team in 2013) across the four communities. For 94% of visited households,
consent was given for the intervention to be explained and for all household members to be
listed on the CHiPs’ electronic register, and 120,272 individuals aged15 years were
enumerated.
Among enumerated individuals, consent to participate in the PopART intervention was
high among women (86%) but lower among men (64%), because it was harder for CHiPs to
contact men at home compared with women (Fig 1). Among women, consent to participate
was high across all age groups except those aged 15–17 years; among men, consent to partici-
pate was highest among those aged 18–24 and60 years (Table 1).
Even though we applied a stricter definition for knowledge of HIV status after, compared
with before, the R2 annual visit (see Methods), R2 achieved a large increase in the percentage
Fig 1. Enumeration, consent to participation, and knowledge of HIV status, in Round 2.
https://doi.org/10.1371/journal.pone.0197904.g001
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of people who knew their HIV status: from 67% to 84% for women, and from 57% to 79% for
men (Table 1). Knowledge of HIV status following the R2 visit was highest among those aged
Table 1. Cascade from enumeration, through participation and knowledge of HIV status, in Round 2.
Enumerated Consented to
participate
Known HIV
status before
Round 2 visit1
Known HIV
status after
Round 2 visit2
Self-reported
HIV+ in Round
2
Tested with
CHiPs in Round
2
Did not test
with CHiPs in
Round 2,
reported HIV-
negative test in
previous 3
months
Known HIV-
positive3
%4 n %5 n %5 n %5 n %5 n %5 n %5 n
Overall 120,272 75 90,781 63 57,218 82 74,401 10.0 9,073 64 58,073 8 7,255 12.8 11,607
Men 57,901 64 37,265 57 21,249 79 29,618 7.1 2,632 65 24,177 8 2,809 9.3 3,467
Women 62,371 86 53,516 67 35,789 84 44,783 12.0 6,441 63 33,896 8 4,446 15.2 8,140
Men, by age
15–17 3,933 60 2,341 17 391 79 1,846 0.5 12 75 1,754 3 80 0.9 22
18–19 4,725 76 3,570 41 1,475 85 3,049 0.6 23 79 2,832 5 194 1.1 38
20–24 10,391 72 7,908 59 4,636 84 6,613 0.8 65 76 6,031 7 517 2.0 154
25–29 9,257 64 5,902 61 3,603 81 4,805 3.2 187 69 4,057 10 561 5.8 344
30–34 8,079 59 4,776 62 2,956 78 3,717 8.0 382 61 2,894 9 441 12.1 580
35–39 6,666 58 3,939 65 2,553 78 3,078 14.3 562 54 2,146 9 370 18.0 707
40–44 5,126 58 2,959 67 1,984 76 2,245 19.6 580 48 1,425 8 240 23.1 683
45–49 2,984 58 1,741 66 1,146 77 1,335 20.0 349 50 862 7 124 24.1 420
50–54 2,001 59 1,183 68 803 75 888 19.4 230 48 569 8 89 21.6 255
55–59 1,432 64 914 67 610 73 665 15.1 138 50 458 8 69 16.5 151
60–64 976 70 679 63 427 68 464 8.0 54 53 363 7 47 8.4 57
65+ 1,791 76 1,353 62 845 67 913 3.7 50 58 786 6 77 4.1 56
Women, by age
15–17 4,567 71 3,265 21 674 80 2,620 0.5 16 76 2,470 4 134 1.6 52
18–19 5,983 87 5,197 53 2,730 88 4,556 1.3 66 80 4,182 6 308 3.4 175
20–24 14,143 89 12,619 69 8,673 88 11,069 4.9 622 74 9,302 9 1,145 8.5 1,069
25–29 10,230 90 9,157 74 6,769 86 7,917 11.9 1,090 64 5,823 11 1,004 16.2 1,482
30–34 7,834 88 6,895 75 5,206 85 5,842 18.9 1,302 56 3,887 9 653 23.4 1,613
35–39 5,982 85 5,085 76 3,842 84 4,271 24.6 1,251 50 2,562 9 458 28.1 1,428
40–44 4,001 82 3,295 76 2,511 82 2,709 28.0 921 46 1,526 8 262 31.0 1,020
45–49 2,634 81 2,129 72 1,543 79 1,673 23.0 490 48 1,020 8 163 25.8 550
50–54 2,356 82 1,936 72 1,402 78 1,502 17.2 332 54 1,045 6 125 19.2 371
55–59 1,644 86 1,407 66 930 73 1,023 13.9 195 53 747 6 81 15.1 212
60–64 1,130 86 967 67 645 69 666 10.4 101 53 515 5 50 10.8 104
65+ 1,867 84 1,564 55 864 60 935 3.5 55 52 817 4 63 4.1 64
1 Counted as knowing HIV status before Round 2 visit if self-reported HIV-positive, reported an HIV-negative test in the previous 12 months, or tested HIV-negative
with CHiPs in Round 1
2 Counted as knowing HIV status following Round 2 visit if self-reported HIV-positive, tested with CHiPs in Round 2, or reported an HIV-negative test result in the
previous 3 months (stricter definition than (1), to fit with the messaging from CHiPs that if it is >3 months since the last HIV-negative test then it is advised that an
individual should accept the offer of testing from CHiPs in order to update their knowledge of their HIV status)
3 “Known HIV-positive” if self-reported or tested HIV-positive in Round 1 and verbally confirmed their HIV-positive status in Round 2, or self-reported HIV-positive
for the first time in Round 2, or tested HIV-positive with CHiPs in Round 2
4 Denominator is all enumerated as a household member
5 Denominator is all who consented to participate in Round 2.
https://doi.org/10.1371/journal.pone.0197904.t001
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18–24 years, for both men (84–85%) and women (88%), and then fell with increasing age
(Table 1).
The percentage of individuals who self-reported HIV-positive as well as those who were
known HIV-positive following the R2 annual visit showed a striking age pattern, with a peak
at age 40–49 years for men and at 35–44 years for women (Table 1). Among individuals who
had self-reported or tested HIV-positive in R1, and participated again in R2, 98% (5,577/
5,700) verbally confirmed their HIV-positive status in R2. Overall, 9.3% of men and 15.2% of
women were known HIV-positive, similar to R1[18].
ART uptake among known HIV-positive individuals at the start and by the
end of Round 2
On the date of the R2 annual visit, 64% of known HIV-positive men and 69% of known HIV-
positive women self-reported that they were on ART (Table 2). This was substantially higher
than at the start of R1 (~50%)[18]. The percentage of individuals on ART showed a striking
age pattern, as in R1, increasing from age 20–24 years and stabilizing at ~80% for men50
years and ~80% for women35 years. Correspondingly, the percentage of known HIV-posi-
tive individuals who were newly diagnosed HIV-positive by the CHiPs in R2 (22%) was much
lower than in R1 (40%), and much higher for younger than older individuals. In terms of abso-
lute numbers, most new HIV-positive diagnoses were among men aged 20–49 years and
women aged 18–44 years.
Among those known to be HIV-positive, 82% of men and 84% of women remained resi-
dent in the same zone of the community at the end of R2 according to the last CHiP visit in R2
(Table 2), with the lowest figures among men aged 20–34 years and women aged 15–29 years.
By the end of R2, among those who remained resident in the same zone of the community,
80% of known HIV-positive men and 81% of known HIV-positive women were on ART
(Table 2). The percentage on ART increased between the start and end of R2 in all age groups,
remaining higher among older than younger individuals at the end of R2, and approached or
reached 90% for men aged45 years and women aged35 years. An ART card number was
recorded for 76% of individuals who reported they were on ART, at the start and/or by the end
of R2.
Retention on ART on the date of first participation in Round 2, among
known HIV-positive individuals who had ever taken ART
On the date of first consenting to participate in R2, 2,345 known HIV-positive men and 5,766
known HIV-positive women either reported they had previously taken ART, and/or they had
reported prior or current use of ART during R1 (S1 Table). Among this group, 93% of men
and 95% of women reported being on ART at the time of the R2 annual visit, and that they
had missed 0 pills in the previous 3 days, with figures of>90% for almost all age groups.
Time from first CHiP referral in Round 2 to ART initiation
Among 3,435 HIV-positive individuals who were not on ART on the date of first participation
in R2 and were referred to HIV care, 1,774 were subsequently recorded as linked to HIV care,
of whom 95% (1,680/1,774) were recorded as initiated on ART. Overall, we estimated that
23%, 39%, 50%, and 67% started ART by 1, 3, 6, and 12 months respectively after first referral
to care in R2 (Fig 2, S2 Table), with a median time to start ART of 6 months. These figures
were considerable improvements compared with R1, when an estimated 42% and 55% had
started ART by 6 and 12 months respectively after first referral to care with a median time to
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start ART of 9.5 months (Fig 2). Overall the time to start ART was slightly slower for women
than men, among men slowest for those aged 20–24 years, and among women slowest for
those aged55 years in R2 (Fig 2, S2 Table).
Table 2. ART uptake among known HIV-positive individuals who participated in Round 2, at the start and by the end of Round 2.
Known HIV+ following Round 2 visit Newly
diagnosed HIV
+ by CHiPs in
Round 2
Self-reported HIV+ at Round 2 annual visit Remained
resident at the
end of Round 2
On ART on
date of last visit
within Round
2, among
individuals
who remained
resident at the
end of Round 2
At Round 2
visit:
Reported
never
previously
registered for
HIV care
At Round 2
visit:
Reported
have
previously
registered for
HIV care, but
not currently
on ART
At Round 2
visit: Reported
currently on
ART
%1 n %1 n %1 n %1 n %1 n %2 n
Overall 11,607 22 2,534 6 749 4 519 67 7,805 83 9,679 81 7,801
Men 3,467 24 835 6 224 5 179 64 2,229 82 2,845 80 2,269
Women 8,140 21 1,699 6 525 4 340 69 5,576 84 6,834 81 5,532
Men, by age
15–17 22 45 10 0 0 0 0 55 12 100 22 77 17
18–19 38 39 15 5 2 11 4 45 17 92 35 66 23
20–24 154 58 89 6 9 4 6 32 50 74 114 52 59
25–29 344 46 157 11 38 5 18 38 131 73 252 60 152
30–34 580 34 198 8 47 5 29 53 306 74 430 77 332
35–39 707 21 145 7 49 6 39 67 474 81 573 81 467
40–44 683 15 103 7 46 6 40 72 494 85 581 82 478
45–49 420 17 71 4 17 5 20 74 312 89 375 85 317
50–54 255 10 25 4 9 4 9 83 212 88 225 92 207
55–59 151 9 13 3 5 5 8 83 125 88 133 91 121
60–64 57 5 3 2 1 2 1 91 52 96 55 96 53
65+ 56 11 6 2 1 9 5 79 44 89 50 86 43
Women, by age
15–17 52 69 36 2 1 0 0 29 15 77 40 52 21
18–19 175 62 109 6 11 2 3 30 52 74 129 60 78
20–24 1,069 42 447 9 100 5 52 44 470 73 785 63 498
25–29 1,482 26 392 8 112 5 67 61 911 79 1,172 75 877
30–34 1,613 19 311 6 104 4 69 70 1,129 85 1,374 82 1,127
35–39 1,428 12 177 5 72 4 54 79 1,125 86 1,234 87 1,073
40–44 1,020 10 99 5 49 4 43 81 829 88 901 89 804
45–49 550 11 60 5 26 5 28 79 436 90 496 88 435
50–54 371 11 39 6 21 3 13 80 298 93 344 86 297
55–59 212 8 17 8 18 3 7 80 170 95 201 87 174
60–64 104 3 3 9 9 3 3 86 89 97 101 95 96
65+ 64 14 9 3 2 2 1 81 52 89 57 91 52
1 The denominator for the percentages is the number of known HIV-positive individuals following the Round 2 visit
2 The denominator is the number of known HIV-positive individuals who remained resident at the end of Round 2 according to the last follow-up visit made by CHiPs
in Round 2.
https://doi.org/10.1371/journal.pone.0197904.t002
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Knowledge of HIV-positive status among people living with HIV, among
individuals who participated in Round 2
We estimated there were 3,705 HIV-positive men, and 8,515 HIV-positive women, among all who
participated in R2 (Table 3), in comparison to 3,467 known HIV-positive men and 8,140 known
HIV-positive women (Table 2). Estimated HIV prevalence was therefore 10.3% in men and 16.3%
in women (compared with 9.3% of men and 15.2% of women being known HIV-positive).
An estimated 71% of HIV-positive men and 76% of HIV-positive women knew their HIV-
positive status immediately before the R2 annual visit (“pre-CHiP”), higher for older than
younger individuals, and increasing to ~95% for both men and women by the end of R2
(Table 3, Fig 3).
Among both HIV-positive men and HIV-positive women, pre-CHiP knowledge of HIV-
positive status was very different in those who did, and did not, participate in R1 (in the CHiP
zone in which they were resident in R2). For example, among HIV-positive men who did not
participate in R1 we estimated that immediately before the R2 annual visit 50% knew their
HIV-positive status; the corresponding estimate among those who participated in R1 was 89%
(Table 3).
Fig 2. Time to start ART after CHiP referral to HIV care, estimates from “time-to-event” analysis.
https://doi.org/10.1371/journal.pone.0197904.g002
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Population-level estimates of the first and second 90s, and ART coverage,
among all HIV-positive individuals irrespective of whether they
participated in Round 2
For estimation of the first and second 90s among the total population of people living with
HIV, assumptions are required for individuals who did not participate in R2 (see Methods).
Table 3. 90–90 estimates at the start and end of Rounds 1 and 2, among individuals who participated in the intervention and with extrapolation to the total
population.
First 90 Second 90
Estimated number of
HIV-positive
individuals / total
population, %
Immediately before annual round
visit
End
Round
Immediately following annual round
visit
End
Round
Individuals who participated
Men n / N1 %2 % % % %
Round 2, Overall 3,705 / 35,888 10.3 71 94 64 80
Round 2, did not participate in
Round 1
1,706 / 19,038 9.0 50 91 48 71
Round 2, participated in Round 1 1,999 / 16,850 11.9 89 96 77 86
Round 1, Overall 4,662 / 45,399 10.34 52 89 47 72
Women
Round 2, Overall 8,515 / 52,210 16.3 76 96 69 81
Round 2, did not participate in
Round 1
3,667 / 25,764 14.2 57 93 55 73
Round 2, participated in Round 1 4,848 / 26,446 18.3 89 97 78 86
Round 1, Overall 9,499 / 55,703 17.14 56 92 49 72
Extrapolation to total population
Men n / N3 %2 % % % %
Round 2, Overall 6,521 / 61,332 10.6 67 79 71 81
Round 2, did not participate in
Round 1
3,665 / 36,002 10.2 51 70 63 77
Round 2, participated in Round 1 2,856 / 25,330 11.3 87 92 78 85
Round 1, Overall 6,649 / 61,606 10.84 52 78 54 74
Women
Round 2, Overall 10,690 / 66,106 16.2 75 91 71 82
Round 2, did not participate in
Round 1
4,805 / 33,910 14.2 58 86 61 76
Round 2, participated in Round 1 5,885 / 32,196 18.3 89 96 79 86
Round 1, Overall 11,037 / 64,305 17.24 56 87 53 73
Men and Women
Round 2, Overall 17,211 /
127,438
13.5 72 87 71 82
Round 1, Overall 17,686 /
125,911
14.0 55 83 53 73
1 n = estimated number of HIV+ individuals among all who participated in the round, N = total who participated in the round = total who consented to participate in
the round AND had health counselling information recorded
2 estimated HIV prevalence
3 n = estimated number of HIV+ individuals among total population, N = total estimated population
4 Round 1 estimates are restricted to individuals aged18 years on the date they were first enumerated in Round 1, whereas Round 2 estimates include those aged 15–
17 years as well as those aged18 years on the date they were first enumerated in Round 2.
https://doi.org/10.1371/journal.pone.0197904.t003
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We estimated there were 6,521 HIV-positive men and 10,690 HIV-positive women in the
total population, among whom 57% (n = 3,705) of HIV-positive men and 80% (n = 8,515) of
HIV-positive women participated in R2 (Table 3). Estimated HIV prevalence was 10.6% in
men and 16.2% in women.
For the “first 90”, we estimated that 67% of the total population of HIV-positive men and
75% of the total population of HIV-positive women knew their HIV-positive status immedi-
ately before the R2 annual visit, increasing to 79% and 91% by the end of R2 (Table 3 and Fig
4). Among HIV-positive men, knowledge of HIV-positive status by the end of R2 was ~70–
80% for those aged 15–49 years and ~90% among those50 years. Among HIV-positive
women, knowledge of HIV-positive status immediately before the R2 annual visit approached
90% among those aged35 years, and by the end of R2 was ~90% among those aged20
years (Fig 5).
For the “second 90”, we estimated that 71% of known HIV-positive men and 71% of known
HIV-positive women were on ART immediately following the R2 annual visit, increasing to
81% and 82% respectively by the end of R2 (Table 3 and Fig 4). Among known HIV-positive
men, the percentage on ART by the end of R2 was >80% among those aged35 years but
Fig 3. First and second 90 estimates, among individuals who participated in Round 2.
https://doi.org/10.1371/journal.pone.0197904.g003
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much lower at ~60% among those aged 20–29 years. Among known HIV-positive women, the
percentage on ART by the end of R2 was approaching 90% for those aged35 years and was
in the range 60–80% for younger women (Fig 5).
We estimated that ART coverage was 65% among HIV-positive men and 75% among HIV-
positive women by the end of R2, compared with the cumulative 90–90 target of 81%, and
close to 81% for HIV-positive men aged50 years and HIV-positive women aged35 years
but lower for younger individuals (Fig 6). It was striking that ART coverage immediately
before the R2 annual visit was substantially higher than immediately before the R1 annual
visit, for both men and women, across the age range (Fig 6).
Among both men and women, population-level pre-CHiP knowledge of HIV-positive
status was very different in those who did, and did not, participate in R1 (in the CHiP zone
in which they were resident in R2). For example, among HIV-positive men who did not par-
ticipate in R1 we estimated that immediately before the R2 annual visit 51% knew their
HIV-positive status; the corresponding estimate among those who participated in R1 was
87%. The disparity remained at the end of R2, with figures of 70% and 92% respectively
(Table 3). There was also a disparity between those who did, and did not, participate in R1
for the second 90; for example, among known HIV-positive men who did not participate in
R1 we estimated that 77% were on ART by the end of R2, compared with 85% among those
who participated in R1 (Table 3). Among individuals who did not participate in R1, the per-
centage who knew their HIV-positive status immediately before the R2 visit was lower, but
increased more by the end of R2, among those who were not resident in the same zone in R1
compared with those who were resident in the same zone in R1 but did not participate (S3
Table); this pattern was also seen for the percentage on ART among those who knew their
HIV-positive status.
The disparities between those who did, and did not participate, in R1 are important in the
context that among the estimated total of HIV-positive men and women, ~55% and ~45%
respectively did not participate (in the CHiP zone in which they were resident in R2) in the
intervention in R1 (Table 3), and ~40% were not resident (in the CHiP zone in which they
were resident in R2) in R1.
Fig 4. 90–90 estimates for the total population, at the start and end of Round 2. Dark blue bars show the estimated
percentage of HIV+ individuals who knew their HIV+ status (first 90 target) and the estimated percentage who were
on ART among those who knew their HIV+ status (second 90 target), immediately prior to the Round 2 annual visit.
Red bars show the same estimated percentages, by the end of Round 2. ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0197904.g004
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Discussion
Summary of findings
After two years of delivering the PopART UTT intervention in four peri-urban/urban commu-
nities in Zambia, with changes in national ART guidelines and programming occurring in par-
allel, substantial progress was made towards reaching 90–90. We estimated that the first 90
was reached among HIV-positive women, that ~80% of HIV-positive men knew their HIV-
positive status, that ~80% were on ART among HIV-positive men and women who knew their
HIV-positive status, and that ART coverage was ~65% among HIV-positive men and ~75%
among HIV-positive women compared with the cumulative 90–90 target of 81%. For the first
90, the figure for men was similar to, and the figure for women slightly higher than, our esti-
mates after one year of the intervention, and for the second 90 and ART coverage they were
~10% higher. The median time to ART initiation after referral to care by CHiPs was nearly
halved in year 2 of the intervention, compared with year 1, among both men and women. The
third 90 may have been reached among HIV-positive individuals who had taken ART, based
on self-reported information on treatment adherence, but with the caveat that self-reported
Fig 5. First and second 90 estimates, with extrapolation to total population in Round 2.
https://doi.org/10.1371/journal.pone.0197904.g005
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information can provide an over-estimate of treatment adherence compared with biological
testing for ART drugs[19] and that treatment adherence is not equivalent to viral suppression.
At the same time, our findings indicate that reaching 90–90 is hard. The PopART interven-
tion is intensive, with each CHIP team responsible for covering a population of ~500 house-
holds over a one-year period, and offering a range of combination HIV prevention services in
addition to universal testing and support for linkage to HIV care. Two years have not been
enough to achieve 90–90.
Comparison with other studies
Our results can be compared with those from the SEARCH CRT, a trial which aims to reduce
HIV incidence through a combination HIV prevention intervention that includes UTT in 16
intervention communities in rural Uganda and Kenya. Each community has a population of
~10,000 people, and it has been reported that among stable residents (defined as those who, at
the time of first enumeration of the study population, had been resident in the community for
6 of the previous 12 months), 90-90-90 was achieved after two years of intervention[20].
Trial interventions include community campaigns, mobile HIV testing in combination with
Fig 6. ART coverage, immediately before Rounds 1 and 2, and by the end of Round 2.
https://doi.org/10.1371/journal.pone.0197904.g006
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multi-disease screening followed by a targeted offer of home-based HIV testing, and various
strategies to support linkage to care and ART initiation and adherence[13, 21]. In the BCPP
CRT, 90-90-90 was close to being achieved at baseline, and very rapid ART initiation has been
achieved among individuals who were not on ART at the time of first participation in the
intervention[22]. In contrast, ART coverage in the UTT intervention communities of the TasP
study in rural South Africa was far below the cumulative 90–90 target after two years of inter-
vention[23], and much lower than what has been achieved after two years in the PopART Arm
A communities in Zambia.
Explanations for our findings, and remaining gaps and how to close them
The main reason why the first 90 has not yet been reached among men is because of difficulties
in contacting them, despite CHiPs regularly working on weekends, early and late in the day,
periodically offering services outside the household at times and places that are anticipated to
be convenient, and offering HIV testing as part of a wider range of services, all of which facili-
tate testing uptake[24–26]. Nevertheless, ~75% of men in the year 2 population participated in
at least one of years 1 and 2.
Progress towards the second 90 has been slower than towards the first 90. Nonetheless,
~70% of known HIV-positive individuals were on ART at the start of year 2, compared with
~50% at the start of year 1, and during year 2 there was an increase across all age groups to
reach the overall figure of ~80% by the end of year 2. The shorter time to initiate ART follow-
ing referral by CHiPs in year 2, compared with year 1, was likely attributable to multiple fac-
tors. These included the increased focus of the CHiPs on linkage to care in year 2, compared
with year 1, together with targetted follow-up of individuals who had been referred but not yet
linked to care; fewer newly diagnosed HIV-positive individuals in year 2 compared with year
1; increasing community acceptance and understanding of the CHiPs, and of ART and UTT,
with time; increased coordination between the CHiPs and the clinic to facilitate linkage to
care; and clinic improvements. It was not possible to implement a “same-day” ART initiation
(on the same day that an individual first links to HIV care) policy but despite this 95% of those
who were known to have linked to care were also known to have initiated ART. For compari-
son with our findings, in the BCPP CRT a high percentage of individuals linked to HIV care
within a short time after referral, facilitated by SMS reminders, incentives following linkage to
care, and follow-up visits to those who did not attend their first clinic appointment; and in the
SEARCH trial a high percentage linked to HIV care by 12 months after referral, facilitated by
streamlined care and a patient-centred approach to care[21, 22].
The main ART coverage gap that remained to be closed after two years of intervention was
among men aged<50 years, women aged<35 years, and individuals who did not participate in
year 1. An important finding from year 2 was the high proportion (~50%) of individuals who had
not participated in year 1, about 80% of whom were newly resident in the area of the community
(CHiP zone) in which they were living at the time of the year 2 visit. Among this group, we esti-
mated that only ~50% of HIV-positive individuals knew their HIV-positive status prior to year 2,
similar to our finding across the total population prior to year 1. This “challenge of mobility” has
also been described in the study population of the TasP trial[27]. This population movement has
slowed, but not reversed, progress towards 90–90 in the PopART study communities.
In year 1 of the intervention ~40% of known HIV-positive individuals were newly diag-
nosed by the CHiPs. Despite the challenge of mobility, and that ~15% of the year 1 population
did not participate in the intervention in year 1, this figure fell to ~20% in year 2. That the fig-
ure was as high as ~20% shows the value of the second year of intervention for diagnosing new
HIV infections, in particular for individuals who had not participated in year 1 but also
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through repeat testing of those who tested HIV-negative in year 1 and those who declined the
offer of HIV testing in year 1 but accepted a test in year 2.
Study strengths and limitations
A limitation has been the relatively high percentage of men whom the CHiPs have not con-
tacted, which limits intervention effectiveness and means that for ~one-third of the male pop-
ulation assumptions have been required to estimate testing and treatment coverage in the total
population. In sensitivity analyses in which the values of HIV prevalence and testing and treat-
ment coverage were varied among participants whose HIV status was not known to CHiPs,
the range of values for coverage against the first and second 90 targets was from ~3% lower to
~2% higher than our central estimates (S4 Table). A strength has been that CHiPs attempted
to reach the entire resident adult population in year 2 of the intervention, irrespective of
whether a household or individual was resident in year 1.
Information on uptake of treatment, and treatment adherence, has relied on self-reported
information; linkage to clinic records has not been possible. However, by year 2 of the inter-
vention CHiPs had in general established good relationships and trust with their clients, and
they have received thorough and ongoing training on electronic data collection, giving overall
confidence in the self-reported data. Also, our estimates of HIV prevalence are compatible
with previous research data[28], and baseline findings among individuals enrolled into the
research cohort study through which the trial primary endpoint will be measured.
Our measure of treatment adherence is a simple one, calculated as a “snapshot” measure on
the date of the annual round 2 visit, but with the advantage that the “third 90” is conceptually
also a “snapshot” measure. The CHiP database, in which all the information recorded by
CHiPs is held, does not allow an individual’s records to be linked if they move from one CHiP
zone to another, limiting which individuals can be included in a “cohort analysis” approach to
measuring retention on ART at fixed time points after ART initiation. In addition, CHiP fol-
low-up visits are made irregularly, not according to a schedule, and CHiPs may try to follow-
up clients but without success.
During year 1 of the intervention, ~38,000 randomly-selected adults were enrolled into a
cohort study across all study communities, to measure the primary endpoint of the trial. For
all individuals who were HIV-positive at enrolment (based on laboratory testing of a venous
blood sample) and were followed up during mid-2016 to mid-2017, their viral load has been
measured. These data will provide an estimate of the percentage of HIV-positive individuals
who were virally suppressed after two-three years of intervention, and a comparison with the
communities that were randomised to standard-of-care.
Conclusion
Overall coverage against the 90–90 targets was high after two years of the PopART UTT inter-
vention, but was lower among men, young adults, those who were resident in year 1 but partic-
ipated for the first time in year 2, and those who were newly resident in the area of the
community in which they were living in year 2. The median time to ART initiation after refer-
ral to care in year 2 was nearly halved compared with year 1, attributable to multiple factors.
The third year of intervention spans October 2016 to ~September 2017, and is expected to
achieve further progress, especially towards the second 90.
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